FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896569101> ?p ?o ?g. }

• W2896569101 endingPage "viii437" @default.
• W2896569101 startingPage "viii437" @default.
• W2896569101 abstract "Background: Flat dosing regimens of NIVO 240 mg every 2 weeks (Q2W) and 480 mg every 4 weeks (Q4W) were approved in the US across indications (not including 480 Q4W in MSI-H or dMMR CRC) and the EU across indications (240 mg Q2W) and in melanoma and renal cell carcinoma (480 mg Q4W) to provide flexible and convenient treatment options than the initially approved 3 mg/kg Q2W weight-based regimen. These changes were supported by model-based bridging of available efficacy and safety data. Methods: NIVO exposures with flat dosing regimens were predicted and compared with 3 mg/kg Q2W dosing for 3817 patients with melanoma, non-small cell lung cancer, renal cell carcinoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, classical Hodgkin’s lymphoma, small cell lung cancer, hepatocellular carcinoma, colorectal carcinoma, and gastric carcinoma. The impact on differences in time-varying exposure on safety were assessed by time-to-event models of Grade (Gr)2+ immune-mediated adverse events (IMAEs) and treatment-related AEs (TRAEs). The impact of differences in early (month 1) exposure on efficacy was assessed by models of tumor growth dynamics and overall survival (OS). Additionally, the potential impact of time-varying exposure on efficacy was assessed by predicting intratumoral programmed cell death 1 (PD-1) receptor occupancy (RO). Results: The predicted time-averaged concentration at steady-state for 240 mg Q2W and 480 mg Q4W was similar to 3 mg/kg Q2W (<6% difference), whereas the peak and time-averaged concentration after the first dose were higher with 480 mg Q4W. The predicted cumulative probability of experiencing Gr2+ IMAEs or TRAEs with NIVO 240 mg Q2W and 480 mg Q4W were similar to 3 mg/kg Q2W (<1% difference at 2 years). The exposure–response relationship of tumor shrinkage and growth rates were flat. Hazard ratios of OS with NIVO 240 mg Q2W and 480 mg Q4W relative to standard-of-care were predicted to be similar to 3 mg/kg Q2W. The median trough intratumoral RO at steady state was predicted to be maintained above 90% for all 3 dosing regimens. Conclusions: The benefit-risk of NIVO 240 mg Q2W and 480 mg Q4W regimens are expected to be similar to 3 mg/kg Q2W, with the added convenience and flexibility for patients and providers. Editorial acknowledgement: Medical writing assistance was provided by Eric Rabinovsky, PhD, of Spark Medica Inc. (US), funded by Bristol-Myers Squibb. Legal entity responsible for the study: Bristol-Myers Squibb. Funding: Bristol-Myers Squibb. Disclosure: X. Zhao J. Shen, B.J. Schmidt, P. Statkevich, T. Kelleher: Employee: BMS. Y. Feng: Owned BMS stock. M. Rashford, S. Agrawal, A. Roy, A. Bello: Employee, Stockholder: BMS. All other authors have declared no conflicts of interest." @default.
• W2896569101 created "2018-10-26" @default.
• W2896569101 creator A5000044132 @default.
• W2896569101 creator A5005738281 @default.
• W2896569101 creator A5010044441 @default.
• W2896569101 creator A5011152885 @default.
• W2896569101 creator A5042806250 @default.
• W2896569101 creator A5050047645 @default.
• W2896569101 creator A5056861119 @default.
• W2896569101 creator A5060067333 @default.
• W2896569101 creator A5072754070 @default.
• W2896569101 creator A5078545719 @default.
• W2896569101 creator A5083885025 @default.
• W2896569101 creator A5087220120 @default.
• W2896569101 creator A5088326622 @default.
• W2896569101 date "2018-10-01" @default.
• W2896569101 modified "2023-09-27" @default.
• W2896569101 title "Model-based assessment of benefit-risk profile of nivolumab (NIVO) flat dosing schedules (Q2W and Q4W) across multiple tumor types" @default.
• W2896569101 doi "https://doi.org/10.1093/annonc/mdy288.103" @default.
• W2896569101 hasPublicationYear "2018" @default.
• W2896569101 type Work @default.
• W2896569101 sameAs 2896569101 @default.
• W2896569101 citedByCount "2" @default.
• W2896569101 countsByYear W28965691012019 @default.
• W2896569101 countsByYear W28965691012022 @default.
• W2896569101 crossrefType "journal-article" @default.
• W2896569101 hasAuthorship W2896569101A5000044132 @default.
• W2896569101 hasAuthorship W2896569101A5005738281 @default.
• W2896569101 hasAuthorship W2896569101A5010044441 @default.
• W2896569101 hasAuthorship W2896569101A5011152885 @default.
• W2896569101 hasAuthorship W2896569101A5042806250 @default.
• W2896569101 hasAuthorship W2896569101A5050047645 @default.
• W2896569101 hasAuthorship W2896569101A5056861119 @default.
• W2896569101 hasAuthorship W2896569101A5060067333 @default.
• W2896569101 hasAuthorship W2896569101A5072754070 @default.
• W2896569101 hasAuthorship W2896569101A5078545719 @default.
• W2896569101 hasAuthorship W2896569101A5083885025 @default.
• W2896569101 hasAuthorship W2896569101A5087220120 @default.
• W2896569101 hasAuthorship W2896569101A5088326622 @default.
• W2896569101 hasBestOaLocation W28965691011 @default.
• W2896569101 hasConcept C121608353 @default.
• W2896569101 hasConcept C126322002 @default.
• W2896569101 hasConcept C143998085 @default.
• W2896569101 hasConcept C197934379 @default.
• W2896569101 hasConcept C2777288759 @default.
• W2896569101 hasConcept C2777472916 @default.
• W2896569101 hasConcept C2777701055 @default.
• W2896569101 hasConcept C2780030458 @default.
• W2896569101 hasConcept C2781413609 @default.
• W2896569101 hasConcept C71924100 @default.
• W2896569101 hasConceptScore W2896569101C121608353 @default.
• W2896569101 hasConceptScore W2896569101C126322002 @default.
• W2896569101 hasConceptScore W2896569101C143998085 @default.
• W2896569101 hasConceptScore W2896569101C197934379 @default.
• W2896569101 hasConceptScore W2896569101C2777288759 @default.
• W2896569101 hasConceptScore W2896569101C2777472916 @default.
• W2896569101 hasConceptScore W2896569101C2777701055 @default.
• W2896569101 hasConceptScore W2896569101C2780030458 @default.
• W2896569101 hasConceptScore W2896569101C2781413609 @default.
• W2896569101 hasConceptScore W2896569101C71924100 @default.
• W2896569101 hasLocation W28965691011 @default.
• W2896569101 hasOpenAccess W2896569101 @default.
• W2896569101 hasPrimaryLocation W28965691011 @default.
• W2896569101 hasRelatedWork W2966375918 @default.
• W2896569101 hasRelatedWork W4280556106 @default.
• W2896569101 hasRelatedWork W4361941187 @default.
• W2896569101 hasRelatedWork W4361941352 @default.
• W2896569101 hasRelatedWork W4361941416 @default.
• W2896569101 hasRelatedWork W4361954678 @default.
• W2896569101 hasRelatedWork W4362413046 @default.
• W2896569101 hasRelatedWork W4362413055 @default.
• W2896569101 hasRelatedWork W4362413213 @default.
• W2896569101 hasRelatedWork W4362413556 @default.
• W2896569101 hasVolume "29" @default.
• W2896569101 isParatext "false" @default.
• W2896569101 isRetracted "false" @default.
• W2896569101 magId "2896569101" @default.
• W2896569101 workType "article" @default.